Evidence map›Paper›PMID 41315401›Full record

ArticleScientific reports2025

Cisplatin-encapsulated zeolitic imidazolate framework-8 nanosystem enhanced radiosensitivity of non-small cell lung cancer.

Ran Yang, Hongxin Xie, Huijuan Wu, Xinyu Liu, Jiang Luo, Linzhi Han, Mini Zhang, Zhirong Bao, Yan Gong, Conghua Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ran YangDepartment of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Hongxin XieDepartment of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Huijuan WuThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xinyu LiuTianjin Eye Hospital, Tianjin, China.
Jiang LuoDepartment of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Linzhi HanDepartment of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Mini ZhangDepartment of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Zhirong BaoRadiotherapy Center, Zhongnan Hospital of Wuhan University, Wuhan, China. bao_zhirong@163.com.
Yan GongTumor Precision Diagnosis and Treatment Technology and Translational Medicine, Hubei Engineering Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China. yan.gong@whu.edu.cn.
Conghua XieDepartment of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China. chxie_65@whu.edu.cn.

Funding

Medical Science and Technology Innovation Platform Construction Support Project of Zhongnan Hospital of Wuhan University PTXM2025001Regional Science and Technology Innovation Project of Hubei Province 2024EIA001Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University ZNJC202312
6 · The paper itself

Abstract

Lung cancer is one of the most lethal tumors worldwide, of which non-small cell lung cancer (NSCLC) accounts for 80-90% of cases. For patients with locally advanced but surgically unresectable NSCLC, radiotherapy is the fundamental treatment. With the extensive research on nanomaterials, they have been investigated as drug delivery platforms or radio-sensitizing reagents in the treatment of NSCLC. We successfully synthesized the nanoparticles encapsulated cisplatin (CDDP) and iron ions (Fe

Indexed as

Carcinoma, Non-Small-Cell LungCisplatinLung NeoplasmsMetal-Organic FrameworksNanoparticlesRadiation ToleranceZeolitesA549 CellsAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationDrug CarriersHumansImidazolesAntineoplastic AgentsCisplatinDrug CarriersImidazolesMetal-Organic FrameworksZeolitesChemotherapy drugDrug delivery systemLung adenocarcinomaRadiotherapy

Identifiers

PMID41315401
PMCPMC12663482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.